-
Aclarion adds Beverly Hills spine practice to CLARITY trial
-
Aclarion signs second commercial deal with Weill Cornell Medicine
-
Aclarion reports 196% growth in scan volumes for Q1
-
Aclarion names Daniel Keefe commercial director for western US
-
Aclarion partners with Weill Cornell Medicine for spine pain study
-
Echo Lake Capital calls for Aclarion board member resignation
-
Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.
-
Aclarion adopts one-year stockholder rights plan
-
Aclarion says cash runway extends into 2028, ends equity facilities
-
Aclarion partners with Source Healthcare to expand Nociscan in Los Angeles
-
Aclarion raises $10.4 million, extends cash runway into 2028
-
Aclarion raises $10.36 million in registered direct offering
-
Aclarion reports 114% quarterly growth in scan volumes, raises $22M
-
Aclarion enrolls first patients at Northwestern, Scripps sites for CLARITY trial
-
Aclarion publishes Nociscan article in spine surgery journal
-
Aclarion names Jason Brosniak commercial director for eastern U.S.
-
Aclarion hires Dan Isherwood as UK commercial director
-
Aclarion reports 89% surge in scan volumes, advances trial
-
Aclarion presents MR spectroscopy pain biomarker tech at London conference
-
Aclarion to Present at the LD Micro Main Event XIX
-
Aclarion, Inc. (ACON) PT Raised to $22 at Ascendiant Capital
-
Aclarion reports 132% growth in Nociscan scan volume
-
Aclarion (ACON) postpones annual shareholder meeting to July 21
-
Aclarion, Inc. (ACON) PT Lowered to $20 at Ascendiant Capital for 1:27 Stock Split
-
Aclarion (ACON) Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives
-
Aclarion (ACON) Announces 1:27 Reverse Share Split
-
Aclarion (ACON) Announces Expansion Plans with RadNet Affiliates in NY and NJ
-
Aclarion (ACON) Announces First Commercial Agreement with Scripps Health
-
Aclarion (ACON) Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy Data Processing
-
Aclarion (ACON) Announces CLARITY Trial for Nociscan Now Fully Funded
-
Aclarion (ACON) to Showcase NOCISCAN Technology at the Selby Spine Conference
-
Aclarion (ACON) Announces Revised Split Ratio and Timing for Reverse Stock Split
-
Aclarion (ACON) Prices 144M Share Offering at $0.10/sh
-
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
-
Aclarion (ACON) Files for 27.52M Share Offering by Selling Stockholders
-
Aclarion (ACON) Files for 20M Share Offering by Selling Stockholders
-
Aclarion's (ACON) Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
-
Aclarion (ACON) Enters $10M ATM
-
Aclarion (ACON) Files $50M Mixed Shelf
-
Aclarion (ACON) Provides Corporate Update on Nociscan AI Technology Milestones
-
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
-
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
-
Aclarion (ACON) Files $50M Mixed Shelf
-
Ascendiant Capital Starts Aclarion, Inc. (ACON) at Buy
-
Aclarion (ACON) Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution
-
Aclarion (ACON) Announces Updated Product Release That Enhances User-Experience, Scalability, and Security for Nociscan Solution

